The drugmakers of America and Great Britain will launch the new medicine clinical research of hepatitis B in China

The drugmakers of America and Great Britain will launch the new medicine clinical research of hepatitis B in China
News from China News Agency Beijing on December 10 (reporter Zeng LiMing) Nearly 280 million people are infected by hepatitis B and virus in Asia area including China, in order to provide more effective therapeutic medicines for chronic hepatitis B patient in this area, American lucky scientific company of Germany will unite and treat the clinical experimental study of new medicine of hepatitis B with British drugmaker Glenn plain SmithKline in China Mainland. This is information that an forum of expert whom a reporter held from then on today obtains.
Scientific President, John of company in lucky Germany. Kindness, emperor of horse, claim chemical name of medicine this " rich the intersection of horse and acid take the place of 2 pyrrole furan ester (Viread) Wei, good fortune of promise, " It is new the intersection of nucleoside and all kinds of acid that go against, duplicate the intersection of enzyme and inhibitor, can it pass, interfere with the intersection of hepatitis B and the intersection of polymerase and function, DNA of virus, inhibit the duplication of hepatitis B and virus, virus year reducing the serum and liver while organizing quantity.
It is reported, lucky Germany had already signed this medicine to treat the transfer agreement that adult's chronic hepatitis B and virus infected patent usufruct with Ge Lan plain SmithKline in Asian countries on the 24th last month, define Glenn plain SmithKline has listing right of China of this medicine alone, and is responsible for the registration of medicines in China. Two companies will expand coverage of agreement, including Japanese and other countries in Asia together.
Expert reveal medicine this is besides using for treating hepatitis B, indication include with resisting against duplicate virus medicines, unite while being other also, treat the adult HIV to infect; Have already got and used sanctioning in U.S.A., European Union, Turkey, Australia, New Zealand and Canada clinically at present. Expert predict the intersection of China and clinical research carry on three year, invite from three to four to finish, merchandize.
Glenn plain the intersection of SmithKline and person in charge say right to treat hepatitis B China medicine demand relatively loud, can benefit more patients while introducing the high-quality medicine; At time when this medicine applies for the registration, will continue cooperating with Chinese Ministry of Public Health, in order to improve making a diagnosis and giving treatment infrastructure, improve medical worker's engineering level and offer support.
Meanwhile, promote existingly to treat the hepatitis B medicine and enter the medical insurance catalogue, reduce patient's burden; Explore the way to serve countryside, the medicine to improve the rural area is supplied, make the rural patient get the treatment of the advanced medicine too. (End)
|